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Abstract 
PADI4 post-translationally converts peptidylarginine to citrulline. PADI4 can disrupt the 
apoptotic process via the citrullination of histone H3 in the promoter of p53-target genes. 
The current study focused on PADI4 expression in various subtypes of oesophageal car-
cinoma (EC) by immunohistochemistry, western blotting and real time PCR. The study 
also  investigated  the  effect  of  bile  acid  deoxycholate  (DCA)  on  PADI4  expression  in 
Eca-109 cells that originated from EC. Apoptosis and DCA-induced toxicity were ana-
lyzed by TUNEL, MTT assay and flow cytometry. Additionally, the present study inves-
tigated the correlation between single nucleotide polymorphism (SNP) in PADI4 gene 
and EC risk in Chinese population using Illumina GoldenGate assay. Compared with 
paraneoplastic tissues, the transcriptional and translational levels of PADI4 were signif-
icantly elevated in oesophageal squamous cell carcinoma (ESCC, n=9) and oesophageal 
adenocarcinoma (EAC, n=5) tissues. Immunolabeling detected expression of PADI4 in 
ESCC tissues (98.56%, n=139), EAC samples (87.5%, n=16) and oesophageal small cell 
undifferentiated carcinoma (91.7%, n=12) but not in normal tissues (0%, n=16). Further-
more, PADI4 levels is positively correlated with the pathological classification of ESCC 
(p=0.009). PADI4 expression levels were consistent with the number of apoptotic cells in 
the  induced  Eca-109  cells.  rs10437048  [OR=  0.012831;  95%  CI,  0.001746~0.094278; 
p=1.556×10-12]  were  significantly  associated  with  decreased  risk  of  EC,  whereas 
rs41265997 [OR=12.7; 95% CI, 0.857077~33.207214; p=3.896×10-8] were significantly asso-
ciated with increased risk of EC. rs41265997 in exon 3 of PADI4 gene is non-synonymous 
and converts ACG to ATG resulting in a threonine /methionine conversion at position 
274  of  the  protein.  Haplotypes  GC  that  carries  the  variant  alleles  for  rs2501796  and 
rs2477134  was  significantly  associated  with  increased  risk  of  EC  (frequency=0.085, 
p=0.0256, OR=2.7). The results suggest that PADI4 expression is related to the tumor-
igenic process of EC and the DCA-induced apoptosis. The PADI4 gene may be a valid EC 
susceptibility gene. 
Key words: Peptidyl arginine deaminase type 4 (PADI4/PAD4), oesophageal squamous cell car-
cinoma (ESCC), oesophageal adenocarcinoma (EAC), deoxycholate (DCA), apoptosis, genotyping, 
susceptibility, haplotype. 
Introduction 
The peptidylarginine deaminase (PAD) enzyme 
post-translationally modifies arginine, converting it to 
citrulline in the presence of Ca2+ in a process known as 
citrullination.  PADI4,  one  of  the  five  different 
isoforms of PAD, is associated with rheumatoid ar-
thritis (RA) in some populations (1, 2). By immuno-
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histochemistry,  western  blot  analysis  and  real  time 
PCR, we detected the significant expression of PADI4 
in  many  tumor  tissues  from  the  colon,  duodenum, 
oesophagus, fallopian tube, gall gladder, lung, ovary, 
parotid,  pancreas,  prostate,  rectum,  small  intestine, 
stomach, thyroid and uterus (3, 4). We also observed 
PADI4 co-localization with cytokeratin (CK) in some 
tumor tissues, preventing the caspase-mediated deg-
radation of CK via citrullination, a process that may 
contribute  to  abnormal  tumor  cell  apoptosis  (3). 
However,  PADI4  expression  in  various  subtypes  of 
tumors from the same organ has not been well char-
acterized,  and  the  relationship  between  PADI4  ex-
pression and patients’ clinical parameters have never 
been carefully investigated. 
The incidence of oesophageal cancer (EC) is in-
creasing in both developing and developed countries 
(5). Oesophageal cancer is comprised of oesophageal 
squamous  cell  carcinoma  (ESCC)  and  oesophageal 
adenocarcinoma (EAC), which have distinct etiologi-
cal  and  pathological  characteristics.  In  the  current 
study,  we  investigated  the  expression  of  PADI4  in 
ESCC  and  EAC  cells  to  determine  if  its  expression 
level correlated to the histological grades and stages 
of  the  tumors.  It  has  previously  been  reported  that 
bile acid deoxycholate (DCA) promoted the tumour-
igenesis of EC and induced cell apoptosis (6-9). In this 
study, we investigated how DCA affected apoptosis 
and PADI4 expression in cultured EC cells. In addi-
tion, we investigated the susceptibility of PADI4 to EC 
in the Chinese Han population.  
Materials and Methods  
Patients and EC sample preparation 
Samples of EC, which included nine samples of 
ESCC and five samples of EAC, were obtained during 
excision surgery in Shandong Tumor Hospital (Jinan, 
China). Normal tissues located 5 cm away from the 
corresponding tumors were collected during the sur-
gery  as  controls.  Tumor  diagnosis  was  verified  by 
histological methods according to the World Health 
Organization  (WHO)  classification  system.  Tissue 
arrays  containing  183  oesophageal  tissue  sections 
were  commercially  obtained  from  Chaoying  Biosci-
ence  (Shanxi,  China).  The  slides  contained  ESCC 
(n=139),  EAC  (n=16),  oesophageal  small  cell  undif-
ferentiated  carcinoma  (n=12),  and  normal  tissues 
(n=16). Clinical data, including the age, sex, clinical 
pathological  diagnosis,  and  origin  of  every  partici-
pant, were provided by the manufacturer.  
Fresh  anticoagulated  blood  was  collected  from 
patients with EC (n = 83, 60 males and 23 females). 
The patients had a mean age of 57.2 years. The pa-
tients were selected from the same population living 
in the Shandong area of Northern China. The diagno-
sis of EC was determined by barium X-ray tests, CT 
examination, oesophageal cytology examination and 
oesophagoscopical examination. A total of 67 healthy 
people (female 28) having a mean age of 48.0 years. 
The blood donors with no evidence of any personal or 
family history of other serious illness were used as 
controls. Control individuals were age-matched and 
from  the  same  geographical  area  as  patients  diag-
nosed with EC. The blood samples were collected in 
Monovette tubes containing 3.8% sodium citrate.  
All  participants  gave  their  written  consent  to 
participate in the study and to allow their biological 
samples to be genetically analyzed. Approval for the 
study was given by the Ethical Committee of Shan-
dong Academy of Medicinal Sciences. 
Anti-PADI4 antibody  
The PADI4 antibody was prepared by immun-
izing  rabbits  using  oligo-peptides 
(FGDSCYPSNDSRQMH)  specific  to  the  amino  acid 
sequence  of  PADI4.  The  immuno-specificity  of  the 
antibody was verified in previous studies (3, 4, 10). 
Immunohistochemistry  
Tissue samples were fixed in 10% neutral buff-
ered formalin and embedded in paraffin. Tissue sec-
tions  were  deparaffinized  and  rehydrated  using 
standard procedures. To repair the antigen, the sec-
tions were heated at 95 ℃ for 10 min in citrate buffer 
solution (Sigma, USA) and then incubated with En-
dogenous Peroxidase Inhibitor (MaixinBio, China) for 
30 min at room temperature. After washing with PBS 
buffer  (0.132  M  NaCl,  0.0066  M  K2HPO4,  0.0015  M 
KH2PO4 in distilled water, pH 7.6), sections were in-
cubated  with  the  anti-PADI4  antibody  overnight  at 
4℃.  The  immunoreaction  was  processed  using  the 
UltraSensitive  TM  S-P  kit  (Maixin-Bio,  China)  ac-
cording  to  the  manufacturer’s  instructions,  and  im-
munoreactive  signals  were  visualized  using  a  DAB 
substrate  that  stains  the  target  protein  yellow.  Cell 
structures were counterstained with hematoxylin. 
Immunofluorescence 
The tissue sections were processed as described 
above. After three washes with PBS buffer, the tissue 
sections were treated with pre-immune serum for 30 
min  to  improve  immunoreaction  specificity.  The 
slides were incubated with the PADI4 antibody at 4℃ 
for  12  h  and  then  washed  with  PBS. 
TRITC-conjugated  5-goat  anti-rabbit  IgG  (ZSG-BIO, 
China)  antibody  was  added  to  the  slides,  and  the 
slides were incubated for 40 min at room temperature. Int. J. Biol. Sci. 2011, 7 
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Immunofluorescence was observed with a Nikon 50i 
fluorescence microscope (Nikon, Japan). To determine 
antibody specificity and optimize antibody dilution, a 
series  of  control  slides  were  prepared  as  follows: 
primary antibodies only, secondary antibodies only, 
normal rabbit serum and normal goat serum.  
A semi-quantitative image analysis and scoring 
system was applied to evaluate PADI4 immunofluo-
rescent  expression.  This  scoring  system  assigns  the 
following  values,  corresponding  to  the  intensity  of 
fluorescent  signals:  <20  (no  expression),  20-30  (low 
expression),  30-50  (moderate  expression)  and  >50 
(strong expression). 
The correlation between the expression levels of 
PADI4 and clinical indices were evaluated using the 
χ2-test.  SPSS  11.5  software  (USA)  was  used  for  the 
analyses, and P < 0.05 was considered significant. 
Cell culture  
Eca-109, an ESCC cell line, was cultured in RPMI 
1640 medium (Hyclone Thermo, USA) supplemented 
with 10% foetal ox blood serum at 37℃ in a humidi-
fied atmosphere with 5% CO2. Cells were incubated 
with increasing concentrations of DCA (0, 10, 25, 50, 
75, 100, 150, 200, 250 and 300 μM) for 24 hr. 
Western blot analysis  
ESCC  (n=5)  and  EAC  tissues  (n=5)  were  ob-
tained  during  excision  surgery.  Sample  tissues  (200 
μg) were homogenized with RIPA lysis solution (Be-
yotime) and centrifuged at 16000 g for 5 min at 4 ℃. 
The supernatant was  collected, and protein concen-
trations were determined using the BCA Protein As-
say Kit (Beyotime). Total protein was also extracted 
from  Eca-109  cells  by  the  same  method.  Ten  mi-
crograms  of  total  protein  was  separated  on  a  12% 
SDS-polyacrylamide gel and transferred onto a PVDF 
membrane.  Membranes  were  incubated  with  the 
PADI4 antibody at a dilution of 1:2000 overnight at 4 
℃. Membranes were rinsed with wash solution and 
incubated  with  sheep  anti-rabbit  IgG  conjugated  to 
alkaline phosphatase (Jackson). Immunosignals were 
visualized  with  the  Protein  Detector  BCIP/NBT 
Western Blot Kit (Beyotime) following the manufac-
turer’s instructions. The quantification was conducted 
using  ImageQuant  5.2  software.  A  separate  mem-
brane prepared in the same manner was probed with 
an anti-GAPDH antibody (Santa Cruz, USA) to nor-
malize sample loading. 
Real-time PCR 
Total  RNA  was  extracted  using  Tri-blue  (Be-
yotime) from ESCC (n=5) and EAC tissues (n=5) and 
their corresponding healthy tissue samples. Concen-
trations of total RNA were determined with a spec-
trophotometer.  Quantitative  PCR  analysis  was  per-
formed with a LightCycler 480 thermocycler (Roche). 
Gene-specific primers were designed using the PADI4 
mRNA sequence in Genbank (NM012387) and were 
as  follows:  forward 
5’-GACTTCAACGGGCTCATTC-3’  and  reverse 
5’-GGACCGATGACTCGTTTGA-3’.  The  forward 
primer  for  human  GAPDH  was 
5’-TGGCACCCAGCACAATGAA-3’  and  the  reverse 
primer  was  5’-CTAAGTCATAGTCCGCCTAG 
AAGCA-3’. cDNA was prepared with 1 μg of total 
RNA  from  each  sample  using  random  hexamer 
priming  and  reverse  transcription  with  the  Prime-
ScriptTM  RT-PCR  Kit  (TaKaRa).  A  387-bp  DNA 
fragment was produced by first strand cDNA synthe-
sis with the primers described above, cloned into the 
PGEM-T Easy Vector (Promega), and verified by se-
quence  analysis.  Taqman  real-time  PCR  was  per-
formed in 10 μl reaction mixtures containing 5 μl of 
SYBR  Green (TaKaRa), 1  μl of each primer, 1 μl of 
cDNA  and  2  μl  of  H2O.  The  following  optimized 
thermal cycling program was used: 1 cycle of 10 s at 
95℃, 45 cycles of 5 s at 60℃ and 10 s at 72℃, and one 
cycle of 30 s at 65℃. The level of GAPDH mRNA was 
used as a reference to normalize sample loading. For 
each tumor sample, two reactions were performed at 
the same time. One reaction was performed to deter-
mine the mRNA level of the target gene, and the se-
cond was performed to determine level of GAPDH. 
The  experiment  was  performed  in  triplicate.  PCR 
products were confirmed by melting curve analysis. 
The relative expression of mRNA was calculated us-
ing the comparative threshold cycle (Ct) method ac-
cording to the following formula: Ratio = 2–ΔΔCt = 
2-ΔCt (sample), where ΔCt = Ct of target genes – Ct of 
endogenous control gene (GAPDH). The relative tar-
get gene expression was normalized in comparison to 
GAPDH mRNA. Copy numbers of PADI4 mRNA in 
the samples were calculated automatically by the data 
analysis software. 
Cell proliferation assay 
Eca-109  cells  (3×104)  were  plated  in 
flat-bottomed micro-titer plates and incubated for 24 h 
at 37℃ in 5% CO2. Cells were incubated either with 
increasing concentrations of DCA (0-350 μM) for 24 h. 
Following  the  treatment,  MTT 
(3-[4,5-dimethylthiazo-2-yl]-2,5-diphenyl  tetrazolium 
bromide) (Amoresco) was added to the culture. After 
24 h, absorbance was measured at 490 nm with spec-
trophotometer. Cell proliferation is expressed as the 
percentage of cells that remained in cultures treated 
with DCA relative to their untreated controls. Int. J. Biol. Sci. 2011, 7 
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TUNEL assay 
Cell  apoptosis  was  analyzed  using  the  In  Situ 
Cell Death Detection kit (Roche) based on the terminal 
TUNEL  technique.  Cells  were  cultured  on  chamber 
glass culture slides in the presence of DCA. To avoid 
apoptotic  cells  losing  adherence  to  the  slides,  the 
slides  were  coated  with  polylysine.  After  the  cells 
were  treated  with  DCA  for  the  indicated  time,  the 
slides were fixed overnight in 100 g/L formaldehyde, 
treated with proteinase K and H2O2, and labeled with 
dUTP in a humidified chamber at 37℃ for 1 h. The 
cells that did not receive TdT enzyme were used as 
the negative control.  
Flow cytometry by annexin V-FITC and PI stain-
ing 
The cultured cells treated with DCA were col-
lected  and  pelleted  at  1200  U/min.  Pellets  were 
washed twice with cold PBS and then resuspended in 
binding buffer at a concentration of 1×106 cells/mL. 
One hundred microlitres of the solution (1×105 cells) 
was transferred to each of two 5 ml culture tubes. Five 
milliliters of annexin V-FITC (Sigma) and 5 μl of pro-
pidium iodide (PI) (Sigma) were added to each 100 μl 
reaction.  The  cells  were  gently  vortexed  and  incu-
bated  for  15  min  at  room  temperature  in  the  dark. 
Then 400 ul of binding buffer was added. Flow cy-
tometry (FCM) was performed with a FACSCalibur 
(BD Biosciences) within one hour of staining. 
Genomic DNA isolation and genotyping  
Genomic DNA was extracted from whole blood 
samples  with  the  Omega  E-Z  96  Blood  DNA  kit 
(Omega, USA) according to the manufacturer’s pro-
tocol. DNA samples were dissolved in deionized wa-
ter. The concentration and quality of DNA samples 
were measured using a spectrophotometer at 260 nm 
(A260)  and  280  nm  (A280).  An  A260/A280 ratio  of 
1.7-1.9 was considered to be highly pure DNA. Elec-
trophoresis was also used to examine the quality and 
integrity of DNA. 
TagSNPs located in PADI4 were determined by 
searching the HapMap database. TagSNPs were de-
termined under conditions of a pair-wise r2 ≥ 0.8 and 
minor allele frequencies (MAF) over 0.05. SNPs that 
were in exons and untranslated regions (UTR), as well 
as promoters and introns within 500 bp near exons, 
were also selected. Candidate SNPs were submitted to 
Illumina for a design score. The Illumina Assay De-
sign Tool filtered out SNPs that were not suitable for 
the  Illumina  platform,  such  as  insertions/deletions, 
tri-  and  tetra-allelic  SNPs,  and  SNPs  that  were  not 
uniquely  localized.  Finally,  74  SNPs  with  a  design 
score of “1” were selected; they span 57,000 bases of 
the chromosome. These SNPs included 4 tag SNPs, 13 
coding SNPs, 2 SNPs at the 3’UTR, 55 SNPs in introns 
and 5 SNPs in the promoter region. These SNP sites, 
locations and MAF are described in Table 1.  
We  performed  genotyping  using  a  cus-
tom-designed Illumina 96-SNP VeraCode microarray 
(Illumina). Genotyping was completed at the Beijing 
Institute of Genomics. The genotyping was conducted 
with  the  BeadXpress  Reader  using  the  Illumina 
VeraCode  GoldenGate  Assay  kit.  500  ng  of  sample 
DNA were used per assay. Genotype clustering and 
calling  were  performed  using  BeadStudio  software 
(Illumina). 
 
 
 
Table 1 SNP information 
Serial 
num-
ber 
SNP ID  Chr posi-
tion 
Locus  Al-
lele 
Protein 
residue 
1  rs16825114  17633206  5' near gene  C/T     
2  rs11579504  17633246  5' near gene  A/G     
3  rs2501795  17633499  5' near gene  A/G     
4  rs2501796  17633522  5' near gene  A/G     
5  rs2477134  17633572  5' near gene  A/C     
6  rs2477133  17633892  5' near gene  G/T     
7  rs35381732  17634740  missense  A  His [H] 
8  rs2501799  17635072  intron  A/G     
9  rs2477132  17635141  intron  G/T     
10  rs1886301*  17635411  intron  C/T     
11  rs1635598  17657321  intron  A/G     
12  rs35111705  17657650  intron  -/G     
13  rs882537  17660047  intron  C/T     
14  rs34309058  17660468  missense  A  Thr [T] 
15  rs874881  17660499  missense  C  Ala [A] 
16  rs1548323  17660697  intron  A/G     
17  rs1748034  17662541  intron  G/T     
18  rs2240340  17662639  intron  A/G     
19  rs1748033  17662662  synonymous  C  Leu [L] 
20  rs12733102  17662705  missense  C  Thr [T] 
21  rs1621005  17662751  intron  C/G     
22  rs1748032  17662804  intron  A/G     
23  rs1748031  17662907  intron  A/T     
24  rs12089685  17664480  intron  C/T     
25  rs11588132  17664615  missense  C  Thr [T] 
26  rs1635586  17664770  intron  C/T     
27  rs1635585  17664813  intron  A/C     
28  rs1635583  17665003  intron  C/G     
29  rs2477152  17665064  intron  A/G     
30  rs11203368*  17666508  intron  C/T     
31  rs35236764  17668036  intron  -/C     
32  rs1748021  17668270  intron  C/T     
33  rs16825565  17668508  synonymous  T  Pro [P] Int. J. Biol. Sci. 2011, 7 
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34  rs41265995  17668509  missense  A  Ser [S] 
35  rs34743635  17668570  missense  T  Leu [L] 
36  rs41265997  17668606  missense  T  Met [M] 
37  rs1748020  17668609  missense  T  Phe [F] 
38  rs1748019  17668976  intron  C/G     
39  rs1748016  17671140  intron  A/G     
40  rs1635571  17672729  intron  A/G     
41  rs2240338  17674185  intron  A/G     
42  rs2240337  17674222  intron  A/G     
43  rs6686575  17674366  intron  C/T     
44  rs2240336  17674402  intron  A/G     
45  rs2240335  17674537  synonymous  A  Arg [R] 
46  rs1635570  17674601  intron  A/G     
47  rs41266005  17674793  intron  C/T     
48  rs12746451  17674821  intron  C/T     
49  rs766449  17674852  intron  A/G     
50  rs12731347  17674865  intron  A/G     
51  rs12731545  17675012  intron  A/G     
52  rs12754450  17675056  intron  A/C     
53  rs3094881  17680807  intron  A/G     
54  rs6683201  17681277  intron  C/T     
55  rs4920600  17681424  intron  A/G     
56  rs35348318  17681492  intron  -/T     
57  rs36097026  17681498  intron  -/T     
58  rs16825849  17682215  intron  C/G     
59  rs10437048  17682719  intron  A/C     
60  rs2301887  17682923  synonymous  T  His [H] 
61  rs1635566  17683157  intron  C/T     
62  rs34213328  17683185  intron  -/T     
63  rs1748011  17683281  intron  G/T     
64  rs1635565  17683332  intron  A/G     
65  rs1635564*  17683526  intron  A/C     
66  rs34481461  17685466  intron  A/C     
67  rs6673924  17686013  intron  C/T     
68  rs6664430  17686051  intron  C/G     
69  rs1635561*  17687027  intron  A/G     
70  rs34170018  17689736  intron  C/G     
71  rs2477150  17689954  intron  A/G     
72  rs34954650  17690376  3' UTR  C/T     
73  rs1408423  17690877  3' near gene  C/T     
74  rs1408422  17690915  3' near gene  A/G     
* represents tag SNP 
 
 
Statistical analysis  
After genotyping, SNP markers were evaluated 
for  significant  deviation  from  the  Hardy-Weinberg 
equilibrium (HWE). SNPs were analyzed for associa-
tion by comparing the MAF between cases and con-
trols. Associations of SNPs with EC were evaluated 
using odds ratios (OR) with 95% confidence intervals 
(CI). Fisher’s exact test was used for comparison be-
tween  categorical  variables.  P  values  less  than  0.05 
were considered statistically significant. A test of de-
viation  from  HWE  was  performed  for  each  SNP  in 
both case and control population using software Plink 
v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/ 
) (11). Association tests for allele and genotype fre-
quencies for each SNP were also performed using this 
software. Multiple-test correction was performed by 
Plink  v1.07  including  Genomic-control  correction, 
Bonferroni  single-step  correction,  Holm  step-down 
correction and Sidak single-step correction. Linkage 
disequlibrium (LD), coefficient (D′ and r2) and haplo-
type  were  estimated  by  software  Haploview  4.2 
(http://www.broad.mit.edu/mpg/haploview/) (12). 
Results  
Immunodetection of PADI4 in oesophageal tumor 
tissues  
Immunohistochemistry and immunofluorescent 
labeling were performed to determine the expression 
of PADI4 in ESCC and EAC tissues. The enzyme was 
detected in 98.6% (137/139) of ESCC tumors, 87.5% 
(14/16) of EAC tumors and 91.7% (11/12) of small cell 
undifferentiated carcinomas. We failed to detect the 
enzyme in any normal tissues (0/16 cases). In most 
cases, PADI4 was located in the cytoplasm of tumor 
cells. However, for small cell undifferentiated carci-
noma,  PADI4  was  present  in  both  the  nucleus  and 
cytoplasm  of  the  tumor  cells.  The  enzyme  was  not 
significantly detected in normal oesophageal tissues 
except  in  a  few  mesenchymal  cells.  No  signal  was 
observed  in  negative  controls  that  were  incubated 
with either the primary or secondary antibody alone. 
The results of these immunohistochemical studies are 
shown in Figure 1. 
The immunofluorescent signals of PADI4 were 
semi-quantified  using  SimplePCI  software.  Within 
ESCC tissues (n=139), the PADI4 level was positively 
correlated with a pathological classification (p=0.009). 
PADI4 expression was increased in ESCC tissues that 
had  higher  pathological  tumor  grades.  However, 
PADI4  levels  did  not  correlate  with  clinical  tumor 
stage, gender, or age (p＞0.05). These results are pre-
sented  in  Table  2.  These  correlations  were  not  de-
tectable in EAC tumors or small cell undifferentiated 
carcinomas.  Int. J. Biol. Sci. 2011, 7 
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Figure 1. Detecting PADI4 in various oesophageal tumor subtypes using immunohistochemistry (A) and immunoflu-
orescent labelling (B). 1, ESCC tissues; 2, EAC tissues; 3, oesophageal small cell undifferentiated carcinoma tissues; 
4, normal tissues. (SP × 400) 
 
 
Table 2. The correlation of PADI4 levels with clinical 
indexes  
        －  ±  +  ++  P 
Pathological 
grade 
           
  Ⅰ   2  14  34  4  0.009 
  Ⅱ  0  20  24  22   
  Ⅲ  0  5  6  8   
Gender             
Female  0  0  9  22  13  0.253 
Male  1  2  31  44  18   
Age             
＜50  1  0  0  3  1  0.768 
50~60  2  0  16  25  11   
＞60  3  2  24  38  19   
Clinical stage             
  1  0  0  1  0  0.853 
  2  1  17  24  9   
    3  1  23  41  22     
* －: negative; ±:weak positive; +: positive; ++: strong positive 
 
Quantifying PADI4 expression levels by western 
blot analysis and real time PCR  
PADI4 protein levels were quantified by western 
blot  analysis.  The  67  kDa  protein  was  detected  in 
ESCC  (n=5),  EAC  (n=5)  and  corresponding 
non-malignant tissues. The expression level of PADI4 
was  significantly  higher  in  ESCC  and  EAC  than  in 
their corresponding paraneoplastic tissues (p=0.0029 
and 0.0048, respectively). These results are shown in 
Figure 2A, B and C.  
Transcription  of  PADI4  was  quantified  by  re-
al-time PCR. All samples of ESCC and EAC (n=5 for 
each  subtype)  tissues  exhibited  a  higher  level  of 
PADI4 mRNA than the corresponding non-malignant 
tissues (p=0.0114 and 0.0133, respectively). These re-
sults are shown in Figure 3. 
Effect of DCA on cell proliferation and PADI4 
expression in Eca-109 cells 
Cultured Eca-109 cells were treated with DCA at 
different concentrations as described above. The per-
cent of viable cells were assessed using the MTT as-
say. The results indicated that cell proliferation was 
suppressed in the presence of increasing  DCA con-
centrations following 24 hrs of treatment. Cell growth 
was suppressed by 80% after treatment with 300 μM 
DCA for 48 h. The MTT results fluctuated when the 
concentration  of  DCA  was  between  the  range  of  0 
μM-100 μM. These results are shown in Figure 4.  
TUNEL assay was used to analyze apoptosis of 
Eca-109 cells in the presence of DCA. These results 
revealed that DCA-induced apoptosis in Eca-109 cells 
occurred in a dose-dependent manner. Morphology 
indicative  of  apoptosis  was  observed  after  24  h  of 
DCA treatment at 100, 200 and 300 μM concentrations. 
These  morphologic  changes  included  chromatin 
condensation,  membrane  blebbing  and  shrinkage, 
and an increase in apoptotic bodies. Compared to the 
controls,  the  numbers  of  apoptotic  cells  were  in-
creased after the addition of increased DCA concen-
trations. These results are shown in Figure 5.  
The expression level of PADI4 in Eca-109 cells 
was examined by western blot analysis. The protein Int. J. Biol. Sci. 2011, 7 
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levels  were  significantly  increased  in  the  cultured 
cells treated with 100 μM to 300 μM DCA. The ex-
pression level of PADI4 fluctuated when the concen-
tration  of  DCA  was  in  the  range  of  0  μM–100  μM. 
These results are shown in Figure 6A and B. 
Eca-109 cells treated with 0-300 μM DCA were 
stained with annexin V and PI to assess apoptosis by 
FCM.  Both  “early”  apoptotic  cells  and  “late”  apop-
totic  cells  were  annexin  V-FITC-positive  and 
PI-positive.  The  percentage  of  apoptotic  cells  was 
significantly increased after 100 μM to 300 μM treat-
ment  of  DCA.  When  the  expression  of  PADI4  was 
increased, there was also an increase in the percentage 
of  apoptotic  cells.  Furthermore,  the  percentage  of 
apoptotic cells significantly corresponded to the ex-
pression  levels  of  PADI4,  and  fluctuated  when  the 
concentration of DCA was in the range of 0 μM-100 
μM. These results are shown in Figure 6C. 
 
 
 
Figure 2. Detecting PADI4 expression with western blotting. A. Western blotting shows expression of PADI4 in ESCC 
tumors (lanes 1-5) and paraneoplastic tissues (lanes 6-10). B. Western blotting detected expression of PADI4 in EAC 
tumors (lanes 11-15) and paraneoplastic tissues (lanes 16-20). C. PADI4 expression is significantly increased in ESCC 
and EAC tissues as compared to that in paraneoplastic tissues. (p=0.0029 and 0.0048, respectively). Lanes 1-2, PADI4 
protein levels in ESCC and corresponding paraneoplastic tissues; Lanes 3-4, PADI4 protein levels in EAC and corre-
sponding paraneoplastic tissues. Int. J. Biol. Sci. 2011, 7 
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Figure 3. Detecting PADI4 expression levels using real time PCR. Real time PCR measurement of PADI4 mRNA levels 
in ESCC (lane 1, n=5) and EAC (lane 2, n=5) samples. This expression was normalized to the expression of GAPDH. 
These results indicate that PADI4 transcription is significantly increased in ESCC and EAC tissues compared to that in 
the oesophageal paraneoplastic tissues. (p=0.0114 and 0.0133, respectively). 
 
 
Figure 4. MTT measurement of cell proliferation. Cultured Eca-109 cells were incubated with 0-350 µM DCA. Cell 
proliferation was suppressed by increasing concentrations of DCA after 24 h of treatment. The error bars represent 
the standard deviation from 3 replicate measurements. 
 
 
Figure 5. TUNEL detection of Eca-109 cell apoptosis after DCA treatment. Cells were stained with acridine orange 
and then imaged with a fluorescent microscope. Apoptotic cells are indicated with arrows. Int. J. Biol. Sci. 2011, 7 
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Figure 6. Detecting PADI4 expression and apoptosis of Eca-109 cells after DCA treatment. A. The expression level of 
PADI4 in the cultured cells was analyzed using western blotting. B. The result was normalized to the expression of 
GAPDH. C. Apoptosis of cultured Eca-109 cells was measured with FCM. Eca-109 cells were treated without DCA (1) or 
with DCA at 10 μM (2), 25 μM (3), 50 μM (4), 75 μM (5), 100 μM (6), 150 μM (7), 200 μM (8), 250 μM (9) and 300 μM (10). 
The error bars represent the standard deviation from 3 replicate measurements. 
 
 
Single SNP and haplotype analysis  
We genotyped 74 SNPs within the PADI4 gene. 
All  SNPs  yielded  usable  genotyping  data  and  the 
study sample success rate was 98.1%. Differences in 
the allele and genotype frequencies between cases and 
controls  were  compared.  Overall,  two  SNPs 
(rs10437048 and rs41265997) were significantly asso-
ciated with a risk of EC. rs10437048 [OR= 0.012831; 
95%  CI,  0.001746~0.094278;  p=1.556×10-12]  were  sig-
nificantly  associated  with  decreased  risk  of  EC, 
whereas  rs41265997  [OR=12.7;  95%  CI, 
0.857077~33.207214;  p=3.896×10-8]  were  significantly 
associated  with  increased  risk  of  EC.  Another  SNP 
rs2501796  was  associated  with  EC  before  multi-test 
correction (p=0.02). However, the association was not 
detected following Bonfferni correction. Table 3 con-
tains the allele frequencies, genotype frequencies and 
the unadjusted and adjusted p-values after the statis-
tical  analysis  of  these  SNPs.  All  SNPs  retained  in 
analyses  were  in  Hardy-Weinberg  equilibrium 
(P>0.05) in the overall samples. Other SNPs located in 
PADI4 gene were not significantly different in allelic 
or genotypic frequencies between the EC patients and 
controls. In addition, age and sex were matched be-
tween case and control (p＞0.05). We also performed 
multivariate  logistic  regression  analysis  using  soft-
ware Plink v1.07 to test the correlations between the 
SNP and ESCC. The p values after logistic regression 
is also shown in Table 3. Int. J. Biol. Sci. 2011, 7 
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Linkage  disequilibrium  (LD)  analysis  was  per-
formed within the 74 SNPs genotyped. Pair-wise D′ 
values between all SNPs were calculated to determine 
the extent of LD. LD analysis defined five blocks in 
the PADI4 region. These results are shown in Figure 
7. The second block is the largest and most extensive, 
at 8.2 kb in length. Both rs10437048 and rs41265997 
were not localized in any block. 
Haplotypes  analysis  was  performed  using 
Haploview 4.2. Twelve different haplotypes in these 
blocks  were  identified.  Haplotype  AA,  AC  and  GC 
were  detected  in  block  1  (frequencies  as  0.796,  0.12 
and  0.085,  respectively).  Haplotype 
GGGCGGCAAGCCAAG,  ACAAAAGGTAAGGGA 
and  ACAAAAGGTAAGGGG  were  in  block  2  (fre-
quencies  as  0.541,  0.358  and  0.022,  respectively). 
Haplotype AAG and GCA were in block 3. Haplotype 
GG and AA were in block 4 (frequencies as 0.596 and 
0.366, respectively). Haplotype AC and CA (frequen-
cies as 0.743 and 0.247, respectively) were in block 5. 
We omitted  the  haplotypes whose frequency under 
0.05. In haplotype analysis using logistic model, we 
assigned  the  most  frequent  haplotype  as  reference 
(OR=1), then compare other haplotypes with this ref-
erence  haplotype.  The  GC  haplotypes  carrying  the 
variant  allele  rs2501796  and  rs2477134  in  the  first 
block were significantly associated with the increased 
risk of EC (frequency=0.085, p=0.0256, OR=2.7). Other 
haplotypes located in PADI4 gene were not signifi-
cantly associated with the risk of EC (p>0.05). 
Table 3. Allele and genotype frequencies in a case control cohort of patients with EC 
dbSNP 
identity 
 
 
Geno-
type 
No. of pa-
tients with EC 
(%) 
No. of controls 
(%) 
P value  P value after 
multivariate 
logistic regres-
sion 
p value after 
multiple testing 
correction (Bon-
ferroni method) 
odds Ratio (%95 CI) 
rs10437048  allele  C  58(0.3766)  1(0.0077)  2.255×10-14  4.182×10-6  1.55610-12  0.012831 
[0.001746~0.094278]  A  96(0.7234)  129(0.9923) 
genotype  CC  6(0.0779)  0(0)  2×10-14  4.182×10-6  1.556×10-12  - 
CA  46(0.5974)  1(0.0154) 
AA  25(0.3247)  64(0.9846) 
rs41265997  allele  A  46(0.3333)  5(0.0378)  5.646×10-10  1.745×10-9  3.89×10-8  12.7 
[4.857077~33.207214]  G  92(0.6667)  127(0.9622) 
genotype  AA  0(0)  0(0)  1.15×10-12 
 
1.745×10-9  3.89×10-8  - 
AG  46(0.6667)  5(0.0757) 
GG  23(0.3333)  61(0.9243) 
67 controls & 83 cases observed 
 
 
Figure 7. LD plot of the genotyped 74 SNPs in the PADI4 gene. Numbers in squares are D’ values. Red areas represent 
higher levels of LD. Blue areas represent LD comparisons with a low estimation confidence. Dark triangles represent 
haplotype blocks. Int. J. Biol. Sci. 2011, 7 
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Discussion 
We  previously  demonstrated  the 
over-expression and absence of PADI4 in a variety of 
malignant  and  normal  tissues,  respectively  (4).  The 
present study focused on PADI4 expression in a co-
hort of oesophageal tumors. In comparison to normal 
oesophageal  tissues,  immunohistochemistry  showed 
the increased expression of PADI4 in ESCC tumors, 
EAC tumors and small cell undifferentiated carcino-
mas. Real time PCR and  western blot analysis con-
firmed the significantly higher PADI4 expression in 
ESCC and EAC tissues compared to that in parane-
oplastic tissues. These results agree with our previous 
findings. Furthermore, we found that PADI4 expres-
sion  directly  correlated  to  the  pathological  tumor 
grade of ESCC tissues; increased PADI4 correlated to 
more severe cases of the disease. We recently reported 
that  the  expression  level  of  PADI4  is  related  to 
Pathological  Tumour-Node-Metastasis  (pTNM)  in 
serious cystadenocarcinoma. The tumors at T1 and T2 
stages  of  pTMN  had  strong  expression  of  PADI4, 
whereas  the  tumors  at  T3  and  T4  stages  exhibited 
weak or moderate PADI4 staining (10). Studies from 
other groups have also reported that PADI4 plays a 
role in tumourigenesis. Cuthbert et al. and Wang et al. 
found that the citrullination of PADI4 prevented ar-
ginine methylation of histone H3 and H4 during the 
transcriptional  activation  of  oestrogen-responsive 
genes (13, 14). Yao et al. and Li et al. reported that 
PADI4 repressed expression of p53-mediating genes, 
including  OKL38,  p21,  CIP1  and  WAF1,  by  deami-
nasing  the  methylated  arginine  sites  in  histone  H3, 
which consequently interrupted the apoptotic process 
and the cell cycle (15, 16). We also demonstrated the 
citrullination  of  cytokeratin,  antithrombin  and  fi-
bronectin, proteins known to be involved in abnormal 
apoptosis, high coagulation, disordered cell prolifera-
tion and aberrant differentiation (3, 4). 
Studies  have  shown  that  duodenal  reflux  con-
tributes to the development of EC (17-19). Bile acids 
are  major  constituents  of  the  gastroesophageal  re-
fluxate and have an important role in malignant de-
velopment in the oesophagus (20, 21). Previous stud-
ies have demonstrated that bile acids cause mucosal 
injury, induce cyclooxygenase-2 (COX-2) expression, 
and promote tumourigenesis and apoptosis (22, 23). 
Bile acids, in particular DCA, inhibit cell proliferation 
and are potent inducers of apoptosis in several cell 
types, including hepatocytes and colonic cells (24, 25). 
Zhang R et al. reported that DCA could inhibit growth 
and induce apoptosis of Eca-109 cells (26). However, 
the exact molecular mechanism of how DCA contrib-
utes to  this process has  not  been elucidated. In the 
present study, we found that DCA significantly stim-
ulated the expression of PADI4 and promoted Eca-109 
apoptosis. Furthermore, the percentage of apoptotic 
cells  significantly  correlated  with  PADI4  expression 
levels. This result not only confirmed other previous 
studies, but it also demonstrated an important role of 
PADI4  in  DCA-induced  apoptosis.  Liu  GY  et  al. 
demonstrated  that  PADI4  over-expression  induced 
haematopoietic  cell  apoptosis  and  suggested  that 
PADI4 could induce apoptosis mainly through arrest 
of  the  cell  cycle  through  a  mitochondria-mediated 
pathway (27). Tanikawa C et al. recently reported that 
DNA  damage  induced  the  citrullination  of  various 
proteins in a p53/PADI4-dependent manner (28). 
As described above, PADI4 is increased in ma-
lignant tumors, and the level of this expression is di-
rectly  related  to  tumor  development  in  ESCC  and 
serious  cystadenocarcinoma.  However, 
over-expression  of  PADI4  enhanced  apoptotic  cell 
death  of  cultured  HL-60,  Jurkat  (human  acute  leu-
kaemic T cells), and Eca-109 cells (27). These observa-
tions remain controversial, and the reason for them is 
yet  unclear.  Most  of  these  previous  studies  were 
conducted with cultured cells under non-physiologic 
conditions, and as such, these results probably do not 
reflect  the  physiologic  function  of  PADI4.  Citrulli-
nated  proteins  not  only  comprise  histones  and  cy-
tokeratin,  but  also  extracellular  matrix  components 
such  as  antithrombin,  fibrin  and  fibronectin  (3,  4). 
These extracellular matrices are also involved in ab-
normal apoptosis, increased coagulation, disordered 
cell proliferation and cell differentiation (29). Thus, it 
is  possible  that  in vitro  experiments  show  different 
results from in vivo studies. Further study is needed to 
understand  the  exact  pathogenic  mechanism  of 
PADI4 in tumourigenesis. 
In this study, 74 SNPs located in the PADI4 gene 
were genotyped within the Han Chinese population. 
The  results  indicated  that  two  SNPs  at  rs104437048 
and rs41265997 were significantly associated with EC 
risk in the population, indicating that PADI4 may be a 
valid EC susceptibility gene. The SNP at rs41265997 is 
located  in  exon  3  of  PADI4  gene  and  is 
non-synonymous.  The  mutation  converts  ACG  to 
ATG  resulting  in  a  Threonine  /Methionine  conver-
sion at position 274 of the PADI4 protein. The amino 
acid substitution in a region of the protein could sig-
nificantly  affect  the  protein  secondary  structure  or 
function. 
After  haplotype  analysis,  a  significant  correla-
tion to EC was observed when haplotype frequencies 
of the patients were compared with that of the health. 
GC  haplotype  carrying  the  variant  alleles  for 
rs2501796 and rs2477134 in block 1 was significantly Int. J. Biol. Sci. 2011, 7 
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elevated in the EC patients. Block 1 is located in the 
promoter  of  PADI4  gene.  It  is  possible  that  genetic 
variation mediates the gene expression by alternating 
the gene’s regulatory mechanism. Dong et al. found 
that  oestrogen  regulates  the  expression  of  PADI4 
through both the classical and nonclassical pathways 
(30). In the classical way, oestrogen binds to the oes-
trogen receptor to form a complex and then regulates 
PADI4 expression via the oestrogen response element 
on  the  promoter.  In  the  non-classical  pathway,  the 
oestrogen-oestrogen  receptor  complex  acts  on  the 
transcription  factors  AP-1,  NF-Y,  and  SP-1,  which 
bind to the PADI4 promoter to specifically regulate 
PADI4 expression. Stacey SN et al. analyzed 304,083 
SNPs  and  observed  significant  association  signals 
from the loci at 1p36 and 1q421p36. The most signifi-
cant  signals  were  from  rs7538876  on  1p36  and 
rs801114 on 1q42 (31). The candidate genes in the 1p36 
locus  contain  PADI4;  their  previous  finding  corre-
sponds  exactly  to  our  results.  Suzuki  et  al.  used  a 
case-control  linkage  disequilibrium  study  to  show 
that PADI4 is a susceptible locus for RA. They found 
that rs2240340/padi4-94 in intron 3 was significantly 
associated with RA. They also found that susceptible 
mRNA  had  more  stable  versus  non-susceptible 
mRNA in vitro (32). In our study, rs2240340 did not 
show a strong association with EC. It is possible that 
PADI4 has different genetic effects on these diseases 
by the utilization of different pathogenic pathways. 
In  summary,  we  demonstrated  the  increased 
expression of PADI4 in different types of oesophageal 
cancer. The expression level of PADI4 was positively 
related to the pathological classification of ESCC. We 
also demonstrated that apoptosis corresponded to the 
expression of PADI4 in cultured EC cells treated with 
DCA. Furthermore, we found that PADI4 may be a 
valid EC susceptibility gene by single SNP and hap-
lotype analyses.  
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